Health Technology · Pharmaceuticals: Major · NSE: ABBOTINDIA · data 2026-10-09
Abbott India Limited
Health check: Strong (7.2/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹26,000
Market cap
₹54,462 cr
P/E
34.2
P/B
—
ROE
34.5%
ROCE
39.1%
Debt / equity
0.04
Dividend yield
2.05%
1-year return
-13.1%
52-week high
₹30,655
52-week low
₹25,135
Operating margin
27.5%
Growth
| Revenue (last 12 months) | ₹7,004 cr |
| Net profit (last 12 months) | ₹1,615 cr |
| Sales growth, 3 years (yearly) | 9.0% |
| Profit growth, 3 years (yearly) | 17.8% |
Chart patterns
- Double top — forming (key level ₹25,135)
Similar companies
Alkem Laboratories Ltd. (ALKEM) · Glenmark Pharmaceuticals Limited (GLENMARK) · Biocon Limited (BIOCON) · Gland Pharma Ltd. (GLAND) · IPCA Laboratories Limited (IPCALAB)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ABBOTINDIA in NSE Scanner →